ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bristol-Myers Squibb and Alder Biopharmaceuticals will jointly develop and commercialize the monoclonal antibody ALD518, which has completed early Phase II clinical trials as a rheumatoid arthritis treatment. BMS will pay $85 million upfront and up to $964 million in potential milestone payments in return for the right to develop ALD518 for all indications except cancer. Alder can also require that BMS invest up to $20 million in a future initial stock offering. Separately, Sanofi-Aventis and Regeneron Pharmaceuticals have extended their monoclonal antibody alliance by five years, through 2017. Starting next year, Sanofi will increase its annual funding commitment by 60% to $160 million. The partners hope to advance four to five therapeutic antibodies into development each year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X